分類彙整:產業訊息

聯生藥抗IgE 抗體新藥UB-221 將進入人體臨床一期試驗

聯生藥(6471)今日表示,已向台灣食品藥物管理署提交創新抗IgE 抗體新藥UB-221 之人體臨床一期試驗申請。此臨床一期試驗主要目的在於評估UB-221 對於使用蕁麻疹一線藥物但仍無顯著效果的慢性自發性蕁麻疹(Chronic Idiopathic Urticaria,CIU) 病患上的安全性與初步療效。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥 進軍陸抗體藥市場

中國醫藥市場成長快速,已躍居全球第二大市場。然其抗體藥物產業才剛起步,2015及2016年的抗體藥物市場規模分別約78及104億元人民幣,隨著人口老齡化、人民經濟能力提升以及產業政策支持,預估2022年將達280~300億元人民幣,未來成長空間相當巨大。目前中國蛋白質/抗體藥物多是以生物仿製藥(Biosimilar) 為主,創新抗體藥將是一塊藍海,未來有很大的成長空間。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United Neuroscience to Present at the Vatican’s Pontifical Council for Culture and the Cura Foundation’s Fourth International ‘Unite To Cure’ Conference in Vatican City

DUBLIN, April 27, 2018 /PRNewswire/ — United Neuroscience, Ltd., today announced that company co-founder Lou Reese will present at the Fourth International Conference, Unite to Cure: A Global Health Care Initiative, held April 26-28, 2018, at the Aula Nuova del Sinodo in Vatican City. The conference, organized by the Pontifical Council for Culture and the Cura Foundation, brings together journalists, advocates and thought leaders to discuss the impact of scientific innovation in medicine on culture and society. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息 | 發表迴響

美國UBI集團暨聯生藥與聯亞藥董事長王長怡博士 受邀在2018揚州生物醫藥論壇中專題演講

美國UBI集團暨聯生藥(6471)與聯亞藥(6562)董事長王長怡博士受邀於25日在揚州月畔灣酒店由揚州國家高新技術產業開發區舉辦的「2018揚州生物醫藥論壇」中給予專題演講。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United Neuroscience and University of Texas Southwestern Medical Center Announce Collaboration to Evaluate Endobody Vaccine Candidates Directed at Tau Protein for the Treatment and Prevention of Alzheimer’s Disease

Candidates Generated with United Neuroscience Endobody Technology Will be Tested at the Center for Alzheimer’s and Neurodegenerative Diseases 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

3/27 生技產業新聞

為台生技產業灌頂工研院、默克合作- 工商時報 新加坡製藥業迎利多進復甦期- 工商 … 繼續閱讀

發表於 產業訊息 | 發表迴響

3/26 生技產業新聞

台灣研發抗肺癌新藥DBPR112 最快5年上市- 自由時報 元富研究部副理傅恒聿 … 繼續閱讀

發表於 產業訊息 | 發表迴響

United Neuroscience Signs Collaboration Agreement with French National Center for Scientific Research (CNRS) Laboratory to Target Protein Associated with Parkinson’s Disease

DUBLIN, March 22, 2018 /PRNewswire/ — United Neuroscience, Ltd., (UNS), today announced that it has entered a research collaboration agreement with the Ronald Melki laboratory at the French National Center for Scientific Research (CNRS) to investigate applications of the United Neuroscience Endobody technology platform in targeting pathogenic forms of alpha-synuclein protein. Under the agreement, United Neuroscience will contribute novel candidates targeting specific protein aggregates using the Endobody technology platform. Researchers in the CNRS laboratory will provide expertise in characterization of these candidates for key properties for their potential in generating therapeutics for Parkinson’s disease and other synucleinopathies. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

USC President, a US Congressman, a Nobel Laureate, United Neuroscience Executives and pioneering scientists are Amongst 2018 award recipients of Brain Mapping Foundation

LOS ANGELES, March 15, 2018 /PRNewswire-USNewswire/ — The Society for Brain Mapping and Therapeutics (SBMT) officially announced today they will hold their 15th Annual World Congress at the Millennium Biltmore Hotel in DTLA from April 13-15, 2018. The event will include more than 400 scientists, engineers, physicians and surgeons where they will discuss pioneering technologies, policies and science advances in the fields including: multimodality imaging, nanoneurosurgery, nanobioelectronics, neurophotonics, cellular therapeutics (stem cell and neuro-immunotherapey), supercomputing, robotics (brain computer interface), neural transplantation and repair (double hand transplants), neuroengineering, Artificial Intelligence (AI), augmented reality and virtual reality in clinical neuroscience as well as computational and predictive modeling. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United BioPharma received approval of the multi-nation, multi-center phase 3 IND from Thailand FDA for UB-421 in HAART substitution trial

United BioPharma (UBP, 6471) announced today that the company receives the approval from Thailand FDA an IND (Investigational New Drug) application for a multi-nation, multi-center, Phase III clinical trial with UB-421 monotherapy as HAART (Highly Active Anti-retroviral Therapy ) substitution in HIV infected patients. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥愛滋病抗體新藥UB-421多國多中心三期臨床試驗獲泰國FDA核准進行

聯生藥今日(6471)表示,其治療愛滋病單株抗體新藥UB-421規劃在台灣、中國與泰國三個地區執行之多國多中心HAART (Highly Active Anti-retroviral Therapy,抗反轉錄病毒療法) 取代性療法第三期臨床試驗,繼2017年11月7日獲得台灣衛福部食藥署 (TFDA) 核准後,今已於2018年3月14日獲得泰國食品藥品監督管理局(ThaiFDA)核發臨床藥物進口許可證(import license) ,核准三期UB-421臨床試驗之進行。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

3/13 生技產業新聞

新藥審查全面加速- 工商時報 生醫力拚2025年挺進兆元產業新藥審查全面加速-  … 繼續閱讀

發表於 產業訊息 | 發表迴響

3/12 生技產業新聞

癌症年輕化趨勢浮現日本免疫細胞療法現曙光- 匯流新聞網 神秘「X疾病」隨時大爆發 … 繼續閱讀

發表於 產業訊息 | 發表迴響

3/9 生技產業新聞

藥明生物(2269): 創新藥Trogarzo獲FDA批准上市- AIMPACT … 繼續閱讀

發表於 產業訊息 | 發表迴響

3/8 生技產業新聞

亞諾法啟動自體T細胞治療實體腫瘤開發與商業化- MoneyDJ理財網 類似病毒的 … 繼續閱讀

發表於 產業訊息 | 發表迴響